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Objective. This study aimed at analyzing the association between recurrent pregnancy loss (RPL) and factor V G1691A (FVL),
prothrombin G20210 (FII); and MTHFR C677T (MTHFR) in Palestinian women. Method. We studied 329 Palestinian women
with RPL and/or stillbirth (SB); and compared them to 402 healthy reproductive Palestinian women. Cases and controls were
tested for the above mutations. Odds ratio (OR) at conﬁdence interval (CI) of 95% was used as a measure of association between
the mutations and RPL. Results. Our statistical analysis showed a slightly increased association, which was not signiﬁcant between
FVL and RPL (OR1.32, 95%CI0.90–1.94), and no association between FII (OR0.84, 95%CI0.38–1.92), MTHFR (OR0.58,
95% CI0.32–1.03), and RPL. Further analysis of RPL subgroups revealed an association between FVL and ﬁrst-trimester loss
(OR1.33, 95%CI0.892–1.989), and second-trimester loss (OR1.13, 95%CI0.480–2.426), both were not statistically signiﬁcant.
Furthermore, the only statistically signiﬁcant association was between FVL and SB (OR2.0, 95%CI1.05–3.70). Conclusion.O u r
analysis had failed to ﬁnd a signiﬁcant association between FVL, FII, MTHFR; and RPL in either the ﬁrst or second trimester. FVL
was signiﬁcantly associated with fetal loss if the loss was a stillbirth.
1.Introduction
Molecular studies of coagulation disorders have led to the
discovery of an increasing number of mutations in the genes
ofthefactorsofcoagulation,termedinheritedthrombophilia
(IT). The most important of this group are factor V gene
LeidenmutationG1691A (FVL),prothrombinG20210 (FII),
homozygosityforthethermolabileofmethyltetrahydrofolate
reductase deﬁciency C677T (MTHFR), antithrombin deﬁ-
ciency, protein C deﬁciency, and protein S deﬁciency [1–
7]. These conditions aﬀect coagulation cascade at diﬀerent
stages; increasing the potential for thromboembolic diseases
(TE) [4, 7].
The importance of IT in obstetrics stems from being
partlyresponsibleforuptohalfofmaternalvenousTE[2,5],
which is one of the direct leading causes of maternal mortal-
ity[2,5,8].WhiletherelationshipofITtoTEisnotdisputed
and has been conﬁrmed by a number of studies [4, 7],
the evidence is conﬂicting regarding the association with
pregnancy complications [1, 5, 6, 8–11]. A delicate balance
between coagulant and anticoagulant factors is needed to
achieve a successful pregnancy [12]. A balanced system
maintains the blood ﬂow to the feto-maternal exchange
unit and promotes trophoblastic proliferation [2, 5, 6]. The
hypercoagulable state that occurs during pregnancy makes
it tempting to postulate that pregnancy association with
a thrombophilic condition may be detrimental through
either repeated pregnancy loss (RPL), intrauterine fetal
death (IUFD), and/or other complications such as placental
abruption, intrauterine growth retardation (IUGR), and
early onset of preeclampsia [2–4, 7, 8].
Researchers have been working on inherited thrombo-
philia to explain RPL, especially that 30–50% of RPL cases
remain enigmatic [1, 13]. RPL is classically deﬁned as three
or more spontaneous fetal losses before the 20th week of pre-
gnancy [8, 11]; however, two or more losses were considered2 Obstetrics and Gynecology International
in some studies [8]. It is a serious condition aﬀecting 5%
of pregnant women with devastating social and medical
consequences [1, 2, 8].
This study aimed at testing the association between
FVL, FII, MTHFR; and RPL in Palestinian women. The fre-
quenciesofthesemutationswerestatisticallycomparedamo-
ng cases with RPL and a control group of healthy women to
test whether signiﬁcant diﬀerences in mutations frequencies
exist between the two groups.
2.MaterialsandMethods
This study protocol was approved by UNFPA and the Rese-
arch and Ethics Committee of Al-Makassed Islamic Chari-
table Society Hospital, Jerusalem; Palestine, and all subjects
involved gave informed verbal consent at the beginning of
the study.
2.1. Study Subjects
2.1.1. Cases. We studied 329 Palestinian females who were
referred to the Molecular Genetics Laboratory at Al-
Makassed Islamic Charitable Society Hospital, Jerusalem,
Palestine; which is the main tertiary hospital serving the
Palestinianterritories.ThesecaseswerereferredbetweenJan-
uary 2002 and April 2006, because of RPL and/or SB. They
were referred by obstetricians from all over the Palestinian
territories as part of their continuing management of the
presenting condition and few were already pregnant and
some were receiving empirical anticoagulant therapy.
RPL was deﬁned as two or more consecutive fetal losses
intheﬁrstorsecondtrimester(upto24weeksofpregnancy),
while stillbirth (SB) as any “child” expelled from its mother
at 24th week of pregnancy or more without showing any sign
of life.
The cases were Palestinian women residing in the
territories who had no prior infertility, TE; or immuno-
logical diseases and had their past pregnancies conﬁrmed
by ultrasound scan. They had normal uterine cavities con-
ﬁrmed mainly by hysterosalpingography and had negative
anticardiolipin proﬁle. Cases with no prior normal parental
karyotyping were excluded. Some cases were still being
investigatedforotherriskfactorsandetiologies, forexample,
infections and endocrinological causes.
Duringthestudyperiod;therewere329casesofRPLwho
fulﬁlled the study criteria; 267 had recurrent ﬁrst-trimester
abortion, 50 had recurrent second-trimester abortions, and
21 had both ﬁrst and second-trimester abortions, as well as
65 who had SB, out of which 45 were associated with RPL.
2.1.2. Control Group. 402 healthy Palestinian women were
recruited.Theywererecruitedfromwomenattendinggynae-
cology clinics at various hospitals (public & NGO) in all the
districts of the Palestinian territories. They were attending
clinics mainly for postpartum checks and contraception but
not infertility. They were 20–45 years of age, nonpregnant,
and had given birth to one or more healthy infants. None
had a history of fetal loss, preeclampsia, IUGR, abruption
placenta, any kind of thrombosis, or known immunological
disease.
All women were living in the Palestinian territories,
and detailed information about the obstetric, medical; and
familyhistorywascollectedbytrainedlaboratorytechnicians
who were aware of the purpose of the study; they used
a standardized medical history form for both cases and
controls.
Cases and controls were tested for the following muta-
tions: factor V G1691A, Prothrombin G20210; and MTHFR
C677T.
2.2. Molecular Diagnosis. DNA was extracted from the blood
specimens using the MasterPure Genomic DNA Puriﬁcation
Kit (Epicentre Technologies, USA) according to the stan-
dard procedure [14]. We used the ampliﬁcation refractory
mutation system (ARMS) as the diagnosing method. ARMS
is an ampliﬁcation strategy in which a polymerase chain
reaction (PCR) primer is designed in such a way in order
to discriminate among templates that diﬀer by a single
nucleotide residue [15, 16].
Genomic DNA (0.2µg) and common normal and
mutated primers (0.1µg) were used in the reaction con-
taining 0.625U of peQlab Polymerase enzyme and MgCl2
at a concentration of 1.5mM in a ﬁnal volume of 25uL.
PCR conditions for factor V G1691A were as follows: initial
denaturation at 98◦C for 2min, 98◦C for 20sec, 56◦Cf o r
35sec, 72◦C for 35sec, for 28 cycles, and ﬁnal extension at
72◦C for 5min.
PCR conditions for prothrombin G20210A were as
follows: initial denaturation at 94◦C for 5min, 94◦Cf o r
15sec,56◦Cfor15sec,72◦Cfor30sec,for33cycles,andﬁnal
extension at 72◦C for 10min.
PCR conditions for MTHFR C677T were as follows:
initial denaturation at 94◦C for 5min, 94◦C for 30sec, 57◦C
for 30sec, 72◦C for 30sec, for 27cycles, and ﬁnal extension
at 72◦C for 5min.
In order to increase speciﬁcity of bands, formamide was
added at a concentration of 3% to the MTHFR C677T
reaction mixture and at 2% to the prothrombin G20210A
mixture. Each ampliﬁed PCR product was analyzed using
2% agarose gel electrophoresis (Tech Comp, Ltd., USA), and
stained with SYBR Green stain. Bands were visualized under
UV illuminator, and photographed with a Polaroid camera
(Fuji Photo Film Co., Japan).
2.3. Statistical Analysis. Exact logistic regression was per-
formed using Stata version 10 software. The Odds Ratio at




Both cases and controls were Palestinian women living in all
districts of the Palestinian territories. The mean age of the
casesandthecontrolswasnotsigniﬁcantlydiﬀerentbuttheir
parity diﬀered signiﬁcantly, the cases had a parity of 1.16 and
the controls had a parity of 3.15 (P = .000) reﬂecting the
eﬀectofRPLonachievingthedesiredfertility.Consanguinity
was signiﬁcantly greater in the cases compared to theObstetrics and Gynecology International 3
Table 1: Selected characteristics of cases and controls.
Characteristic Cases n = 329 Controls n = 402 P value
Age (years) 28.1 28.9 .054
Parity (n) 1.16 3.15 .000
Consanguinity n (%) 109 (33.10%) 99 (24.60%) .006
Family history of TE n (%) 62 (18.80%) 79 (19.70%) .391
Diabetes Mellitus (n) 1 (0.3%) 3 (0.7%) .210
Hypertension (n) 4 (1.2%) 2 (0.5%) .142
Table 2: Number and prevalence of FVL, FII, and MTHFR in the cases and normal controls.
FVL n (%) FII n (%) MTHFR n (%)
Cases
All cases n = 329 77(23.4%) 11 (3.3%) 21(6.4%)
Consang. n = 109 28 (25.7%) 4 (3.7%) 8 (7.3%)
Non-consang. n = 220 49 (22.3%) 7 (3.2%) 13 (5.9%)
RPL n = 309 70 (22.7%) 11 (3.6%) 20(6.5%)
SB n = 65 20 (30.8%) 4 (6.2%) 2(3.1%)
Controls
All controls n = 402 73 (18.2%) 17 (4.2%) 43(10.7%)
Consang. n = 99 21 (21.2%) 7 (7.0%) 11 (11.1%)
Non-consang. n = 303 52 (17.1%) 10 (3.3%) 32 (10.6%)
(i) n = number, (%) = prevalence, consang.= consanguineous, non-consang.= non-consanguineous. (ii) RPL: all cases excluding those with only stillbirth,
SB: cases with stillbirth alone and stillbirth with ﬁrst or second trimester loss.
controls; 33.1% versus 24.6% (P = .006). Other risk factors
andvariableswerecompared,andtheresultsaresummarized
in Table 1.
There were 77 FVL mutations in the case group repre-
senting a prevalence of 23.4%, and there were 73 (18.2%)
carriers in the controls. 70 out of 309 (22.7%) cases with
RPL were carriers of FVL mutations resulting in OR 1.32
(95% CI: 0.89–1.94). 11 out of 309 (3.6%) cases with RPL
were carriers of FII mutations compared to 17 out of the 402
(4.2%) controls, OR 0.84 (95% CI: 0.35–1.92). 20 out of the
309 (6.5%) cases with RPL were homozygous for MTHFR
compared to 43 out of 402 (10.4%) of the control group,
OR 0.58 (95% CI = 0.31–1.03). The results are summarized
in Table 2. Cases and controls were classiﬁed according to
their consanguinity status, numbers, and prevalence for each
category are displayed in Table 2.
Further association was tested after dividing the cases
into3subgroups:groupAincluded267womenwithrepeated
ﬁrst-trimester miscarriage, B included 50 women with
repeated second-trimester miscarriage, and C included 65
women with SB (Table 3).
FVL was higher in the three subgroups of RPL/SB, with
OR in the ﬁrst-trimester subgroup 1.33 (95% CI: 0.892–
1.989), the second-trimester subgroup OR 1.13 (95% CI:
0.480–2.426), and the SB subgroup OR 2.0 (P = .028, 95%
CI: 1.053–3.701). Results are summarized in Table 3.T h e
results for FII and MTHFR and the diﬀerent subgroups are
also summarized in Table 3.
Furthermore, it was of importance to study the associa-
tion of the three mutations to cases with only ﬁrst-trimester
miscarriages and without a prior successful pregnancy
(primary RPL), given that this group seem to display
diﬀerent degrees of association to clinical risk factors in case-
controlstudiesandbehavediﬀerentlyintreatmenttrials.Our
results did not yield signiﬁcant association between the three
mutations and primary RPL. The results are summarized in
Table 3.
The prevalence of the genotypes and the alleles of the
three mutations was analyzed separately; the results are
summarized in Table 4.
4. Discussion
The study subjects were of similar ethnic and social back-
ground and were living in the diﬀerent districts of the
Palestinianterritories.Wecomparedsomecharacteristics,for
example, age, parity, consanguinity; and family history of
TE, which are considered by many researchers as the most
important risk factors. It was thought that alcohol or drug
use were irrelevant in the context of Palestinian women in
the reproductive age. Smoking role in RPL is not yet clearly
deﬁned, and due to extremely low rate of smoking among
young Palestinian women [17]; we did not include it as a
confounder in our study.
Some researchers suggested that RPL is a multifactorial/
polygenetic condition [11], and several of these risk factors
are insuﬃcient independently for leading to RPL. It is when
several intrinsic and extrinsic factors come together in the
same individual that the risk exceeds the threshold and
disease develops [11]. Hence, our decision is to study and4 Obstetrics and Gynecology International
Table 3: FVL, FII; and MTHFR association with RPL Subgroups, SB; and primary RLP.
Subgroups of RPL/SB FVL FII MTHFR
Odds ratio [95% CI] Odds ratio [95% CI] Odds ratio [95% CI]
Group A (n = 267) 1.33 0.79 0.57
(0.892–1.989) (0.305–0.909) (0.297–1.044)
Group B (n = 50) 1.13 — 0.53
(0.480–2.426) (0.102–1.773)
Group C (n = 65) 2.0∗ 1.49 0.27
(1.053–3.701) (0.351–4.759) (0.030–1.065)
Primary RPL (n = 168) 0.719 (0.111–7.901) 0.533 (0.071 + Inf) 0.879 (0.119 + Inf)
Group A: women with repeated ﬁrst-trimester miscarriage, Group B: women with repeated second-trimester miscarriage; Group C: women with SB, primary
RPL: women with only ﬁrst-trimester miscarriages and without a prior successful pregnancy.
∗P = .028.
Table 4: Genotype and allele analysis of factor V Leiden G1691A, MTHFR C677T, and prothrombin (FII) G20210A.
Genotype Allele
FV G1691A G/G (%) G/A (%) A/A (%) G (%) A (%)
Controls (n = 402) 329 (81.8) 69 (17.2) 4 (1) 727 (90.4) 77 (9.6)
Cases (n = 329) 250 (76) 72 (21.9) 7 (2.1) 572 (87) 86 (13)
MTHFR C677T C/C (%) C/T (%) T/T (%) C (%) T (%)
Controls (n = 402) 182 (45.3) 177 (44) 43 (10.7) 541 (67.3) 263 (32.7)
Cases (n = 329) 145 (43.5) 151 (46.8) 33 (9.7) 441 (67) 217 (33)
FII G20210A G/G (%) G/A (%) A/A (%) G (%) A (%)
Controls (n = 402) 385 (95.8) 17 (4.2) 0 787 (97.9) 17 (2.1)
Cases (n = 329) 318 (96.7) 11 (3.3) 0 647 (98.3) 11 (1.7)
reportcaseswhowerebeinginvestigatedforotherriskfactors
and etiologies, for example, infections and endocrinological
causes.
Our analysis indicates a high prevalence of FVL (18.2%)
in the normal controls with an allele frequency (AF) of
9.6% (Table 4). These ﬁgures fall within the range of related
ethnic groups such as Israeli Arabs (25.7%, AF 13.6%)
[18], Jordanians (12.3–15%) [19, 20], and Lebanese (12–
14.4%) [21–23]. They are also congruent with other studies
showing that eastern Mediterranean populations have a high
prevalenceofFVL[23],forexample,GreekCypriots(13.3%)
[24] and Syrians (13.6%) [23]. The narrow diﬀerence in
frequencies among these populations suggests a single origin
of the mutation, which has been proven by haplotype
analysis [25].
The high prevalence of FVL seen in our study has
mitigated the signiﬁcance of association with RPL. It is not
surprising that the high prevalence of FVL was correlated
with a consanguinity rate of 25% in the normal controls and
33% in the RPL group, which could have enhanced inher-
itance of the mutated alleles in this population. Studying
association of consanguineous cases and controls revealed
O.R. 1.16 (95% CI 0.32–3.73), while studying association of
non-consanguineous cases and controls revealed O.R. 0.79
(95% CI 0.29–1.91).
In this background of high consanguinity rates, we had
to analyze and compare the prevalence of the genotypes and
the alleles of the three mutations (illustrated in Table 4). The
detailedanalysisofthediﬀerentallelesofthethreemutations
was in agreement with Hardy-Weinberg equilibrium.
Consanguinity among Palestinians ranges from 24 to
45% [26], and it appears to be the strongest risk factor
for reproductive wastage after age and parity in Palestinian
women (Assaf S., pers. com.). In Egypt, ﬁrst-cousin couples
were found to have higher likelihood of repeated miscar-
riages,stillbirths,andneonataldeathsthancoupleswhowere
less related [27].
Few case-control studies and meta-analysis had shown
a high prevalence of FVL in women with RPL [3, 10, 28–
31] .As y s t e m a t i cr e v i e wo ft h el i t e r a t u r ef o u n da nO Rf o r
the association between RPL and FVL of 2.0 (95% CI 1.5–
2.7; P<. 001) [3]. Reznikoﬀ-Eti´ evant et al. evaluated 260
consecutive white women who had experienced two or more
unexplained losses at less than 10 weeks gestation and found
that 27 subjects (10.3%) were positive for FVL compared
to 11 controls (4.6%) [28]. The authors concluded that the
FVL was signiﬁcantly associated with RPL before 10 weeks
gestation. The study of Grandone et al. also pointed out that
the frequency of FVL is signiﬁcantly higher among women
with RPL and particularly associated with late events [30].
Furthermore,Reyetal.,inameta-analysisofthetopic,found
that FVL was associated with early (OR 2.01, 95% CI 1.13–
3.58) and late (7.83, 2.83–21.67) RPL and late nonrecurrent
fetal loss (3.26, 1.82–5.83) [10].Obstetrics and Gynecology International 5
Our conclusions from the analysis of Palestinian women
showed a statistically signiﬁcant association between FVL
and SB but not between FVL and RPL in the ﬁrst or the sec-
ond trimesters. These ﬁndings are in contrast with the ﬁnd-
ings of the European Prospective Cohort on Thrombophilia
(EPCOT), which compared 571 women with thrombophilia
with 395 control women. They deﬁned miscarriage as a fetal
loss in ≤28 weeks of gestation and stillbirth as a fetal loss in
>28 weeks of gestation. The risk of fetal loss was higher in
women with thrombophilia (OR 1.35). The OR was higher
for SB than for miscarriage; 3.6 versus 1.27. The highest OR
was for SB in women with multiple thrombophilias (14.3)
compared with 2.0 for FVL alone, suggesting a synergistic
eﬀect [31].
In contrast to many studies which showed a signiﬁcant
association between FII and both early and late RPL [3,
10], our results did not show any association between FII
and RPL (Table 2). In addition, the slight association with
stillbirth (OR 1.48, [95% CI; 0.35–4.76]) was not statistically
signiﬁcant.
MTHFR is a metabolic disease which has been associated
with arterial and venous TE [7]. It was of interest to study
MTHFR in women who had RPL because placental infarcts
have been associated with RPL [32]. However, MTHFR was
underrepresented in the RPL group, which is in agreement
with other reports [33, 34]. This may be attributed to folic
acid supplementation, which is widely used especially in the
ﬁrst trimester of pregnancy. Folate status plays a crucial role
in regulating homocysteine level in individuals homozygous
for the MTHFR [33]. Therefore, it is reasonable to assume
that folic acid supplementation may eﬀectively silence the
adverse eﬀects of MTHFR, thus reducing the risk of RPL in
women who are homozygous for this mutation.
Ithasbeenshownthatwomenwithconcurrentpolymor-
phism for FVL, FII, and MTHFR have an increased risk for
TE and RPL than women with only one mutation [31]. We
could not study this association because of the small number
of these combinations in our data.
In conclusion, our study did not ﬁnd a signiﬁcant
association between FVL, FII, and MTHFR and RPL in the
ﬁrst and second trimester. The only signiﬁcant association
was between FVL and SB.
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